Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 5—May 2008

Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru

Sonya S. Shin*Comments to Author , Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
Author affiliations: *Brigham and Women’s Hospital, Boston, Massachusetts, USA; †Instituto Nacional de Salud, Lima, Peru; ‡Programa de Control de Tuberculosis, Lima, Peru; §Partners in Health, Boston, Massachusetts, USA; ¶Centers for Disease Control and Prevention, Atlanta, Georgia, USA; #Socios en Salud, Lima, Peru;

Main Article

Table 4

Considerations for decentralized drug susceptibility testing (DST) capacity for first-line drugs, Peru

Criterion Ideal situation
Drugs to test First-line DST; isoniazid and rifampin most important because empiric treatment regimen and further DST may follow
Reproducibility Because drug-resistant samples identified by regional DST, then referred to National Reference Laboratory for DST to second-line drugs, sensitivity most important
Sample source Direct method optimal for processing 
at local health clinic to minimize turnaround time
Cost per sample Low cost
Time to obtain result Rapid
Technical demand Less technically demanding, less processing time
Biologic safety risk Low biosecurity risk
Required equipment Limited additional equipment 
(refridgerated centrifuge) procured and maintained in local site
Reagents and supplies Commonly used reagents and supplies available through local vendors is preferable

Main Article

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.